Cresco Labs Inc has a consensus price target of $10.46, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from Roth MKM, Wedbush, and Cantor Fitzgerald on March 14, 2024, March 20, 2023, and February 24, 2023. With an average price target of $6.08 between Roth MKM, Wedbush, and Cantor Fitzgerald, there's an implied 188.31% upside for Cresco Labs Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/14/2024 | CRLBF | Buy Now | Cresco Labs | $2.11 | -5.21% | Roth MKM | Scott Fortune | $1.75 → $2 | Maintains | Neutral | Get Alert |
03/20/2023 | CRLBF | Buy Now | Cresco Labs | $2.11 | -5.21% | Wedbush | Gerald Pascarelli | $4.5 → $2 | Maintains | Outperform | Get Alert |
02/24/2023 | CRLBF | Buy Now | Cresco Labs | $2.11 | 575.36% | Cantor Fitzgerald | Pablo Zuanic | → $14.25 | Maintains | Overweight | Get Alert |
12/30/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 575.36% | Cantor Fitzgerald | Pablo Zuanic | $15 → $14.25 | Maintains | Overweight | Get Alert |
12/20/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 18.48% | Cowen & Co. | Vivien Azer | $7 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
12/02/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 113.27% | Wedbush | Gerald Pascarelli | → $4.5 | Initiates | → Outperform | Get Alert |
08/18/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 184.36% | Piper Sandler | Michael Lavery | $9 → $6 | Maintains | Overweight | Get Alert |
08/18/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 610.9% | Cantor Fitzgerald | Pablo Zuanic | $19 → $15 | Maintains | Overweight | Get Alert |
03/24/2022 | CRLBF | Buy Now | Cresco Labs | $2.11 | 326.54% | Piper Sandler | Michael Lavery | $14 → $9 | Maintains | Overweight | Get Alert |
11/15/2021 | CRLBF | Buy Now | Cresco Labs | $2.11 | 800.47% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
11/03/2021 | CRLBF | Buy Now | Cresco Labs | $2.11 | 468.72% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
08/05/2021 | CRLBF | Buy Now | Cresco Labs | $2.11 | 539.81% | Cantor Fitzgerald | Pablo Zuanic | — | Maintains | Overweight | Get Alert |
07/07/2021 | CRLBF | Buy Now | Cresco Labs | $2.11 | 1606.16% | Jefferies | Owen Bennett | — | Initiates | → Buy | Get Alert |
The latest price target for Cresco Labs (OTCQX: CRLBF) was reported by Roth MKM on March 14, 2024. The analyst firm set a price target for $2.00 expecting CRLBF to fall to within 12 months (a possible -5.21% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Cresco Labs (OTCQX: CRLBF) was provided by Roth MKM, and Cresco Labs maintained their neutral rating.
There is no last upgrade for Cresco Labs.
The last downgrade for Cresco Labs Inc happened on December 20, 2022 when Cowen & Co. changed their price target from $7 to $2.5 for Cresco Labs Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cresco Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cresco Labs was filed on March 14, 2024 so you should expect the next rating to be made available sometime around March 14, 2025.
While ratings are subjective and will change, the latest Cresco Labs (CRLBF) rating was a maintained with a price target of $1.75 to $2.00. The current price Cresco Labs (CRLBF) is trading at is $2.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.